Upstart Hldgsの空売り状況は、投資家がUpstart Hldgsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Upstart Hldgs (NASDAQ:UPST) 株価情報, 空売り情報

Upstart Hldgs

Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. Upstart's platform includes personal loans, automotive retail and refinance loans, home equity lines of credit, and small-dollar loans.

Upstart Holdings

Upstart Holdings Inc

Upstream Bio Inc

PROBILITY MEDIA CORP by Probility Media Corp.

Upstryve Inc

EV giant Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) will refresh its more premium car offerings- the Model S and Model X- later this year, senior company executive Lars Moravy said in an interview published on Sunday.
What Happened:&nbsp;Moravy, in an interview with&nbsp;Ryan McCaffrey&nbsp;recorded on Feb.13 and published on Sunday,&nbsp;said that the company intends to show its Model S and X vehicles &#8220;some love&#8221; and refresh them later this year.
Tesla last refreshed the Model S and X in 2021. 
In the past two years, the company has focussed on refreshing its cheaper, mass-market offerings. 
Tesla launched a&nbsp;<a href="https://www.benzinga.com/news/24/02/36921718/youtuber-marques-brownlee-reviews-refreshed-model-3-calls-it-teslas-most-important-car-i-am-impresse" target="_blank" rel="noreferrer noopener">refreshed Model 3 in Aug. 2023&nbsp;</a>in China and in the U.S. months later in January 2024. In January this year, the company also launched a <a href="https://www.benzinga.com/25/02/43772576/tesla-to-start-delivering-shanghai-made-refreshed-model-ys-next-week">refreshed version of its best-selling Model Y SUV. </a>
Moravy said that the company focussed on refreshing the Model 3 and Y first as they are higher volume vehicles and refreshing them was needed for the company to stay competitive. However, the S and X are not going anywhere anytime soon, Moravy said.
&#8220;As Elon says, we definitely there&#8217;s some nostalgia to them and like keeping them around and like we don&#8217;t have any immediate plans to change that,&#8221; he said.
Why It Matters: The refreshes come amid concerns about an aging car lineup. Tesla&#8217;s latest offering is its Cybertruck which it started delivering in Nov. 2023. The vehicle, however, is a truck and caters to a different customer demographic. 
The latest car from Tesla is the Model Y SUV, whose production the company started in January 2020. 
The Model X, however, is Tesla&#8217;s <a href="https://www.benzinga.com/tech/24/12/42496103/teslas-model-s-model-x-and-cybertruck-now-have-the-same-starting-price-which-to-buy">priciest offering in the U.S</a>. The base version of the Model X starts at $84,990, pricier than even the Cybertruck or Model S whose base versions start at $79,990.
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43905539/elon-musk-led-spacex-to-undertake-starships-8th-test-flight-on-friday" target="_blank" rel="noreferrer noopener">Elon Musk&#8217;s SpaceX To Undertake Starship&#8217;s 8th Test Flight On Friday</a></li>
<li></li>
</ul>
Image via Tesla

News

Tech

TSLA

Tesla To Launch Refreshed Model S, X Later This Year, Says Senior Exec

Eyenovia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) ("Eyenovia" or the "Company"), an ophthalmic technology company focused on completing development of its proprietary Optejet&#xAE; device, today announced that it has entered into an amendment to its outstanding senior secured convertible debt due November 1, 2025 (the "Amendment").The Amendment defers the Company's monthly interest and amortization payments from March 2025 through September 2025. Additionally, the Amendment allows the full conversion of the debt into common shares of the Company commencing on April 1, 2025, at a price of $1.68 per share.

EYEN

Eyenovia Allows Full Debt Conversion to Common Shares at $1.68 Starting April 2025, Defers Payments Until September 2025

B of A Securities analyst Steve Byrne upgrades CF Industries Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CF#NYSE">CF</a>) from Underperform to Neutral and maintains the price target from $84 to $84.

Upgrades

Price Target

Analyst Ratings

B of A Securities Upgrades CF Industries Holdings to Neutral, Maintains Price Target to $84

The company has received the "Day 74" notification from the FDA acknowledging the previously submitted New Drug Application (NDA) for Epioxa (Epi-on), its next-generation corneal cross-linking iLink therapy for the treatment of keratoconus, a sight-threatening corneal disease, is sufficiently complete to permit a substantive review.&nbsp;

GKOS

Glaukos Secures FDA Acceptance Of NDA Submission For Epioxa

Ceragon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNT#NASDAQ">CRNT</a>),&nbsp;a leading solutions provider of end-to-end wireless connectivity, today announced the launch of its new innovative, next-gen products: IP-100E, IP-50GP, and EtherHaul 8020FX at Mobile World Congress (MWC) 2025.
&nbsp;
With customers' needs always in mind, Ceragon is unveiling new innovations that will expand its end-to-end offering to both its core business and private networks business worldwide.
<ul>
<li>The IP-100E, powered by&nbsp;Ceragon's in-house proprietary system-on-a-chip, is an innovative, dual-carrier, E-band solution, delivering a game-changing 25 Gbps from one box, and up to 40 Gbps in a 4+0 all-outdoor link.</li>
<li>The IP-50GP, Ceragon's latest split-mount microwave solution, offers a cost-optimized approach to achieving seamless connectivity, and is designed to meet the demands of modern networks, delivering optimal performance without compromising on budget.</li>
<li>Ceragon's EtherHaul 8020FX, a millimeter-wave backhaul solution, offers exceptional ease of installation and operations, cost efficiency, and high capacity — a must-see for anyone tackling demanding backhaul challenges.</li>
</ul>
In addition to the above products, Ceragon's IP-50EX mmW series also features a new model — the IP-50EXA — which offers the best price-performance ratio available in the industry and is already gaining significant traction in the market.
At MWC, Ceragon will also showcase its software and service offerings, including its cutting-edge Network Digital Twin, Smart Activation Key, and an interesting mix of use cases that illustrate how Ceragon enables private network operators to tackle diverse connectivity challenges with tailored, end-to-end solutions.

CRNT

Ceragon Unveils Next-Gen Wireless Connectivity Solutions at MWC 2025, Expanding End-to-End Offerings

Financial Outlook for 2025
Based on the early signs we are seeing that many more of our Medicare patients are able to afford paid therapy in 2025, and the strong patient demand for ORLADEYO to start the year, the company has increased its full year 2025 outlook for global net ORLADEYO revenue to between $535 million and $550 million (previously $515 million to $535 million). The company now expects full year 2025 total revenue (including RAPIVAB (peramivir injection)) will be between $560 million and $575 million (previously $540 million to $560 million).
The increased guidance for ORLADEYO revenues in 2025 also results in an increase in related operating expenses, primarily related to cost of goods sold, distribution costs and higher incentive compensation. The company reiterates the previously provided 2025 non-GAAP operating expense outlook range of $425 million to $435 million (not including stock-based compensation). The revenue related operating expense increases are captured at the higher end of this range.

Biotech

Earnings

Guidance

Health Care

General

BCRX

BioCryst Pharmaceuticals Expects Full Year 2025 Total Revenue Of $560M-$575M Compared To Prior Guidance Of $540M-$560M And Consensus Of 545.31M, The Company Increased Its 2025 Outlook For Global Net Orladeyo Revenue To Between $535M-$550M, Previously $515M-$535M

SYTA

Siyata Mobile Announces New Agreement With IP Access International, Expanding Distribution

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNDA#NASDAQ">VNDA</a>) today announced the publication of an article entitled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S" in Molecular Therapy Nucleic Acids1, a Cell Press partner journal, that describes the development of a novel antisense oligonucleotide (ASO) therapeutic, VCA-894A, for a patient with a rare variant in the IGHMBP2 gene causing Charcot-Marie-Tooth disease Type 2S (CMT2S).

VNDA

Vanda Pharmaceuticals Unveils Potential ASO Treatment for Rare Nerve Disease Charcot-Marie-Tooth Type 2S

The acquisition is expected to close in the first quarter of 2025 and is subject to regulatory approval in Austria and customary closing conditions. Dow Jones's parent company, News Corp, expects to receive a $4 million tax benefit in connection with the transaction.

NOTE

NWSA

Dow Jones Agrees To Acquire Dragonfly Intelligence And Oxford Analytica From FiscalNote For $40M

Unity Software Inc. ("Unity") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>), the leading platform to create and grow games and interactive experiences, today announced its intent to offer, subject to market conditions and other factors, $500.0 million aggregate principal amount of Convertible Senior Notes due 2030 (the "Notes") in a private placement (the "Offering") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Unity also intends to grant the initial purchasers of the Notes an option to purchase, within a 13-day period beginning on, and including, the date on which the Notes are first issued, up to an additional $75.0 million aggregate principal amount of Notes.
The Notes will be general unsecured obligations of Unity and will accrue interest payable semiannually in arrears. Upon conversion, Unity will pay or deliver, as the case may be, cash, shares of Unity's common stock or a combination of cash and shares of Unity's common stock, at its election. The interest rate, initial conversion rate and other terms of the Notes will be determined at the time of pricing of the Offering.
Unity expects to use the net proceeds from the Offering to pay the cost of the capped call transactions described below and, together with cash on hand, if necessary, to repurchase for cash approximately, subject to market conditions, $500.0 million in aggregate principal amount of its 0% Convertible Senior Notes due 2026 (the "2026 Notes") in the Note Repurchase Transactions (as described below). If the initial purchasers exercise their option to purchase additional Notes, Unity expects to use a portion of the net proceeds from the sale of the additional Notes to enter into additional capped call transactions. Unity expects to use any remaining net proceeds from the Offering for general corporate purposes, which may include additional repurchases of the 2026 Notes from time to time following the Offering, and acquisitions or strategic investments in complementary businesses or technologies (although Unity does not currently have any plans for any such acquisitions or investments), working capital, operating expenses and capital expenditures.

Offerings

Unity Announces $500M Convertible Senior Notes Offering, Plans Debt Repurchase and Strategic Investments

B of A Securities analyst Peter Galbo initiates coverage on Smithfield Foods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFD#NASDAQ">SFD</a>) with a Buy rating and announces Price Target of $28.

Initiation

B of A Securities Initiates Coverage On Smithfield Foods with Buy Rating, Announces Price Target of $28

BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.06) by 116.67 percent. This is a 53.57 percent increase over losses of $(0.28) per share from the same period last year. The company reported quarterly sales of $131.53 million which beat the analyst consensus estimate of $130.15 million by 1.07 percent. This is a 40.83 percent increase over sales of $93.40 million the same period last year.

BioCryst Pharma Q4 2024 Adj EPS $(0.13) Misses $(0.06) Estimate, Sales $131.53M Beat $130.15M Estimate

CollPlant Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLGN#NASDAQ">CLGN</a>), or "CollPlant", a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced the expansion of its distribution channels for its Vergenix&#x2122; STR product, in Europe and Asia. VergenixSTR is based on the Company's rhCollagen technology and is intended for the treatment of tendinopathy by promoting healing and repair of tendon injuries in a variety of tendons including the elbow tendon (for treatment of "tennis elbow"), rotator cuffs, patellar tendons, the Achilles tendon, and hand tendons. Specifically, CollPlant recently signed distribution agreements for VergenixSTR with distributor companies located in the Netherlands, Turkey and India, for sales in the territories of the Netherlands, Belgium, Luxemburg ("Benelux"), Spain, India and Turkey.
&nbsp;
The new distributor for Benelux and Spain has expertise in medical device sales, with a focus on orthopedics, and CollPlant made the first shipment to this distributor in February 2025. The distributors in Turkey and India, companies that specialize in medical devices including product distribution capabilities,&nbsp;are finalizing the process with their local regulatory authorities, with an objective to commence VergenixSTR sales in 2025.

CLGN

CollPlant Expands Vergenix STR Distribution to Europe and Asia, Targets Tendon Injury Treatments

Freightos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGO#NASDAQ">CRGO</a>) sees FY2025 sales of $29.000 million-$30.600 million vs $30.23 million analyst estimate.

CRGO

Freightos Sees FY2025 Sales $29.000M-$30.600M vs $30.23M Est

Freightos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGO#NASDAQ">CRGO</a>) sees Q1 sales of $6.700 million-$6.800 million vs $6.80 million analyst estimate.

Freightos Sees Q1 Sales $6.700M-$6.800M vs $6.80M Est

"Given the strength of our safety and target engagement data from our Phase 1 clinical study and the profound unmet need in adults living with Duchenne, we are pleased to have obtained FDA clearance for the ELEVATE-44-102 study," said Dipal Doshi, CEO of Entrada Therapeutics.&nbsp;

TRDA

Entrada Therapeutics Reveals FDA Removal Of Clinical Hold On ENTR-601-44

Freightos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGO#NASDAQ">CRGO</a>) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.09) by 22.22 percent. This is a 16.67 percent decrease over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $6.59 million which beat the analyst consensus estimate of $6.46 million by 2.00 percent. This is a 25.28 percent increase over sales of $5.26 million the same period last year.

Earnings Beats

Freightos Q4 Adj EPS $(0.07) Beats $(0.09) Estimate, Sales $6.59M Beat $6.46M Estimate

BMO Capital analyst Katja Jancic upgrades Century Aluminum (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENX#NASDAQ">CENX</a>) from Market Perform to Outperform and maintains the price target from $22 to $22.

CENX

BMO Capital Upgrades Century Aluminum to Outperform, Maintains Price Target to $22

JP Morgan analyst Eric Joseph upgrades bluebird bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) from Underweight to Neutral.

BLUE

JP Morgan Upgrades bluebird bio to Neutral

During the last three months, 8 analysts shared their evaluations of Janus Henderson Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHG#NYSE">JHG</a>), revealing diverse outlooks from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $46.75, along with a high estimate of $53.00 and a low estimate of $43.00. This upward trend is evident, with the current average reflecting a 6.54% increase from the previous average price target of $43.88.
<img src="https://www.benzinga.com/files/images/story/2025/1740398437_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Janus Henderson Group. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brennan Hawken</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$50.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$53.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Brennan Hawken</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$45.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$46.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$43.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$44.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Andrei Stadnik</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$48.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$45.00</td>
<td>$41.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Janus Henderson Group. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Janus Henderson Group compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Janus Henderson Group's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Janus Henderson Group's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/JHG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Janus Henderson Group analyst ratings.</a>
<h2>Delving into Janus Henderson Group's Background</h2>
Janus Henderson Group provides investment management services to retail intermediary (56% of managed assets), self-directed (23%) and institutional (21%) clients. At the end of September 2024, active equities (63%), fixed-income (21%), multi-asset (14%) and alternative (2%) investment platforms constituted the company's $382.3 billion in assets under management. Janus Henderson sources most of its managed assets from clients in North America (61%), with customers from Europe, the Middle East, Africa, and Latin America (29%) and the Asia-Pacific region (10%) accounting for the remainder.
<h3>Janus Henderson Group: A Financial Overview</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Janus Henderson Group's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 13.36%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Janus Henderson Group's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 16.76%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Janus Henderson Group's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 2.54%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Janus Henderson Group's ROA excels beyond industry benchmarks, reaching 1.67%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.08.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Janus Henderson Group plc Ordinary Shares

The Analyst Verdict: Janus Henderson Group In The Eyes Of 8 Experts

Press Releases

DR Bank Chooses Upstart's Small-Dollar Loan Product to Expand Access to Credit

Advia Credit Union Selects Upstart for Personal Lending

Markets

KBW Announces Index Rebalancing for Fourth-Quarter 2024

Sandia Area Federal Credit Union Selects Upstart for Personal Lending

Upstart to Report Fourth Quarter and Full Year 2024 Earnings on Feb. 11, 2025

Upstart Unveils Enhanced Showroom and Auto Financing Solutions that Boost Dealership Sales, Elevate Customer Experience

Pelican State Credit Union Selects Upstart for Personal Lending

Upstart Announces Fourth Quarter and Full Year 2024 Results

Upstart Appoints Peter Bernard to Its Board of Directors

Holyoke Credit Union Selects Upstart for Personal Lending

ACRE

ARES

CFFN

CGBD

CHCT

CION

CLPR

CSWC

EEFT

EGBN

FFIC

FICO

GWRE

HOOD

IBKR

KREF

KRNY

MAIN

NMFC

NXDT

OCSL

PAYO

PFLT

PKST

PSEC

QTWO

RELY

RWAY

SEIC

SITC

TPVG

TRTX

UPST

VIRT

Ally Financial

American Express

Bread Financial Holdings, Inc. Common Stock

Bread Finl Hldgs

Credit Acceptance Corporation - Common Stock

Credit Acceptance

Capital One Financial Corporation Common Stock

Capital One Finl

Dave

Discover Financial servs

Encore Capital Gr

Enova International

FirstCash Hldgs

FinVolution Group American Depositary Shares

FinVolution Gr

Joint Stock Company Kaspi.kz - American Depository Shares

Kaspi.kz

LendingClub

Lufax Holding Ltd American Depositary Shares, each representing two (2) Ordinary Shares

Comments

Upstart Hldgs

空売り

Upstart Hldgs (NASDAQ:UPST) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル